PepGen has released their Q1 Advocacy Newsletter for 2024, including an update for the Canadian Duchenne muscular dystrophy community regarding the CONNECT1-ED051 clinical trial.
Highlights:
- January 8: PepGen announced that they successfully dosed the first person in the CONNECT1-EDO51 study.
- March 13: PepGen received United States FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51
Get the full update from PepGen and read more about their ongoing enrollment for the CONNECT1-ED051 clinical trial:
PepGen is actively enrolling participants for their clinical trial testing whether their investigational drug, PGN-EDO51, is safe and tolerable for boys and men with Duchenne. Canadian locations:
- Fredericton, New Brunswick – Stan Cassidy Centre for Rehabilitation
- Ottawa, Ontario – Children’s Hospital of Eastern Ontario (CHEO)
- Toronto, Ontario – The Hospital for Sick Children (SickKids)
- Québec, Quebec – CHU de Québec
For information on clinical trial locations, please contact Patient Advocacy.